by editor | Aug 7, 2014 | Clinicians, Participants, Researchers
Lack of data underscores importance of ASPREE trial A large scientific review revealed that aspirin protected people aged 50-65 against gastrointestinal cancer, but was unable to determine cancer benefits for those aged over 70. International researchers, who analysed...
by editor | May 30, 2014 | Participants
High quality data answers important questions Principal Investigator to the Australian arm of the ASPREE trial, Professor John McNeil says health authorities require a high level of evidence about the balance of benefits and risks of aspirin in healthy people...
by editor | Mar 7, 2014 | Clinicians, Participants
ASPREE PI editorial in this week’s ‘Medical Observer’ ASPREE Principal Investigator in Australia, Professor John McNeil discusses what the findings of ASPREE trial may mean to future health care. “Currently, it is not known if low-grade inflammation is...
by editor | Jul 22, 2013 | Clinicians, Participants, Researchers
Not conclusive – seek medical advice first says ASPREE investigator Healthy people of all ages should consult their GP prior to commencing aspirin for disease prevention. That’s the advice from Professor Mark Nelson in response to new research that...
by editor | Mar 12, 2013 | Clinicians, Participants, Researchers
Highlights the need for a clinical trial says Oncologist Medical Oncologist Dr Andrew Haydon, who works on cancer aspects of ASPREE, said that a recent association between aspirin and a reduced risk of developing melanoma, was a call for closer investigation of...
Recent Comments